orforglipron semaglutide comparison A new challenger in the oral GLP-1 race 💊 The landscape for oral weight loss drugs is shifting. Phase 3 data from the ACHIEVE-3 trial reveals that the investigational compound outperformed At ENDO 2025, researchers goal-gut-health Subscription:1 time

orforglipron semaglutide comparison A new challenger in the oral GLP-1 race 💊 The landscape for oral weight loss drugs is shifting. Phase 3 data from the ACHIEVE-3 trial reveals that the investigational compound outperformed At ENDO 2025, researchers goal-gut-health Subscription:1 time

At ENDO 2025, researchers presented data suggesting GLP-1 medications may increase testosterone levels while improving sperm quality in men with obesity and hypogonadism. In contrast, testosterone ...

Primary endpoint During the median follow-up of 20 months(ranging from 6 to 48 months), the incidence of MACEs was significantly lower in the GLP-1RA group (7.63%) compared to the control group (19.85%) (HR 0.444

goal-gut-health

Subscription:1 time

References ¹ Wang W